Top

Published in:

Open Access 01-12-2020 | Kidney Cancer | Research

Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma

Authors: Michael Friedrich, Christine Stoehr, Simon Jasinski-Bergner, Arndt Hartmann, Sven Wach, Bernd Wullich, André Steven, Barbara Seliger

Published in: Journal of Translational Medicine | Issue 1/2020

Abstract

Background

The non-classical human leukocyte antigen (HLA)-G is a strong immunomodulatory molecule. Under physiological conditions, HLA-G induces immunological tolerance in immune privileged tissues, while under pathophysiological situations it contributes to immune escape mechanisms. Therefore, HLA-G could act as a potential immune checkpoint for future anti-cancer immunotherapies. Recent data suggest an aberrant expression of the cAMP response element binding protein (CREB) in clear cell renal cell carcinoma (ccRCC), which is correlated with tumor grade and stage. Furthermore, preliminary reports demonstrated a connection of CREB as a control variable of HLA-G transcription due to CREB binding sites in the HLA-G promoter region. This study investigates the interaction between CREB and HLA-G in different renal cell carcinoma (RCC) subtypes and its correlation to clinical parameters.

Methods

The direct interaction of CREB with the HLA-G promoter was investigated by chromatin immunoprecipitation in RCC cell systems. Furthermore, the expression of CREB and HLA-G was determined by immunohistochemistry using a tissue microarray (TMA) consisting of 453 RCC samples of distinct subtypes. Staining results were assessed for correlations to clinical parameters as well as to the composition of the immune cell infiltrate.

Results

There exists a distinct expression pattern of HLA-G and CREB in the three main RCC subtypes. HLA-G and CREB expression were the lowest in chromophobe RCC lesions. However, the clinical relevance of CREB and HLA-G expression differed. Unlike HLA-G, high levels of CREB expression were positively associated to the overall survival of RCC patients. A slightly, but significantly elevated number of tumor infiltrating regulatory T cells was observed in tumors of high CREB expression. Whether this small increase is of clinical relevance has to be further investigated.

Conclusions

An interaction of CREB with the HLA-G promoter could be validated in RCC cell lines. Thus, for the first time the expression of CREB and its interaction with the HLA-G in human RCCs has been shown, which might be of clinical relevance.

Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018;7:307. https://doi.org/10.12688/f1000research.13179.1.CrossRefPubMedPubMedCentral

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029.CrossRefPubMed

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https://doi.org/10.1038/nrdp.2017.9.CrossRefPubMedPubMedCentral

Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57. https://doi.org/10.1038/nrurol.2010.46.CrossRefPubMedPubMedCentral

Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016;9:45–52. https://doi.org/10.2147/IJNRD.S75916.CrossRefPubMedPubMedCentral

Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer. 2019;17:46–57. https://doi.org/10.1016/j.clgc.2018.10.002.CrossRefPubMed

Vachhani P, George S. VEGF inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol. 2016;14(12):1016–28.PubMed

Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920907504. https://doi.org/10.1177/1758835920907504.CrossRefPubMedPubMedCentral

Considine B, Hurwitz ME. Current status and future directions of immunotherapy in renal cell carcinoma. Curr Oncol Rep. 2019;21:34. https://doi.org/10.1007/s11912-019-0779-1.CrossRefPubMed

10.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68:267–79. https://doi.org/10.1016/j.eururo.2015.02.032.CrossRef

11.

Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012;22:350–8. https://doi.org/10.1016/j.semcancer.2012.03.003.CrossRefPubMed

12.

Friedrich M, Jasinski-Bergner S, Lazaridou MF, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, et al. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer Immunol Immunother. 2019;68:1689–700. https://doi.org/10.1007/s00262-019-02373-1.CrossRefPubMed

13.

Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. Front Immunol. 2014;5:394. https://doi.org/10.3389/fimmu.2014.00394.CrossRefPubMedPubMedCentral

14.

Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, et al. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. J Clin Invest. 2017;127:801–13. https://doi.org/10.1172/JCI82976.CrossRefPubMedPubMedCentral

15.

Friedrich M, Heimer N, Stoehr C, Steven A, Wach S, Taubert H, Hartmann A, Seliger B. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Sci Rep. 2020;10:6499. https://doi.org/10.1038/s41598-020-63403-y.CrossRefPubMedPubMedCentral

16.

Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003;63:4107–11.PubMed

17.

Lin A, Yan WH. Heterogeneity of HLA-G expression in cancers: facing the challenges. Front Immunol. 2018;9:2164. https://doi.org/10.3389/fimmu.2018.02164.CrossRefPubMedPubMedCentral

18.

Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. HLA-G: an immune checkpoint molecule. Adv Immunol. 2015;127:33–144. https://doi.org/10.1016/bs.ai.2015.04.001.CrossRefPubMed

19.

da Silva IL, Montero-Montero L, Ferreira E, Quintanilla M. New insights into the role of Qa-2 and HLA-G non-classical MHC-I complexes in malignancy. Front Immunol. 2018;9:2894. https://doi.org/10.3389/fimmu.2018.02894.CrossRefPubMedPubMedCentral

20.

Jasinski-Bergner S, Reches A, Stoehr C, Massa C, Gonschorek E, Huettelmaier S, Braun J, Wach S, Wullich B, Spath V, et al. Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget. 2016;7:26866–788. https://doi.org/10.18632/oncotarget.8567.CrossRefPubMedPubMedCentral

21.

Jasinski-Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Huttelmaier S, Spath V, Wartenberg R, Legal W, Taubert H, et al. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology. 2015;4:e1008805. https://doi.org/10.1080/2162402X.2015.1008805.CrossRefPubMedPubMedCentral

22.

Dunker K, Schlaf G, Bukur J, Altermann WW, Handke D, Seliger B. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens. 2008;72:137–48. https://doi.org/10.1111/j.1399-0039.2008.01090.x.CrossRefPubMed

23.

Gobin SJ, Biesta P, de Steenwinkel JE, Datema G, van den Elsen PJ. HLA-G transactivation by cAMP-response element-binding protein (CREB). An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes. J Biol Chem. 2002;277:39525–31. https://doi.org/10.1074/jbc.M112273200.CrossRefPubMed

24.

Wang X, Cui H, Lou Z, Huang S, Ren Y, Wang P, Weng G. Cyclic AMP responsive element-binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix metallopeptidase-2/9 and proteins associated with epithelial-mesenchymal transition. Mol Med Rep. 2017;15:4191–8. https://doi.org/10.3892/mmr.2017.6519.CrossRefPubMed

25.

Zhuang H, Meng X, Li Y, Wang X, Huang S, Liu K, Hehir M, Fang R, Jiang L, Zhou JX, et al. Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2. Oncotarget. 2016;7:16325–37. https://doi.org/10.18632/oncotarget.7017.CrossRefPubMedPubMedCentral

26.

Li BX, Gardner R, Xue C, Qian DZ, Xie F, Thomas G, Kazmierczak SC, Habecker BA, Xiao X. Systemic inhibition of CREB is well-tolerated in vivo. Sci Rep. 2016;6:34513. https://doi.org/10.1038/srep34513.CrossRefPubMedPubMedCentral

27.

Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A. HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget. 2016;7:67360–72. https://doi.org/10.18632/oncotarget.11744.CrossRefPubMedPubMedCentral

28.

Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med. 2007;204:1543–51. https://doi.org/10.1084/jem.20070109.CrossRefPubMedPubMedCentral

29.

Fontenot JD, Gavin MA, Rudensky AY. FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6. https://doi.org/10.1038/ni904.CrossRefPubMed

Title: Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma
Authors: Michael Friedrich
Christine Stoehr
Simon Jasinski-Bergner
Arndt Hartmann
Sven Wach
Bernd Wullich
André Steven
Barbara Seliger
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: Journal of Translational Medicine / Issue 1/2020
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-020-02544-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Retraction Note to: Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study

Mutations in fibroblast growth factor (FGF8) and FGF10 identified in patients with conotruncal defects

Endometrial cancer: mapping the global landscape of research

Multi-omics examination of Q fever fatigue syndrome identifies similarities with chronic fatigue syndrome

Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods

A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page